Epigallocatechin gallate inhibits the growth of MDA‑MB‑231 breast cancer cells via inactivation of the β‑catenin signaling pathway

Hong,On‑Yu; Noh,Eun‑Mi; Jang,Hye‑Yeon; Lee,Young‑Rae; Lee,Byoung Kil; Jung,Sung Hoo; Kim,Jong‑Suk; Youn,Hyun Jo

doi:10.3892/ol.2017.6108

Epigallocatechin gallate inhibits the growth of MDA‑MB‑231 breast cancer cells via inactivation of the β‑catenin signaling pathway

Authors:
- On‑Yu Hong
- Eun‑Mi Noh
- Hye‑Yeon Jang
- Young‑Rae Lee
- Byoung Kil Lee
- Sung Hoo Jung
- Jong‑Suk Kim
- Hyun Jo Youn
View Affiliations

Affiliations: Department of Biochemistry, Institute for Medical Sciences, Chonbuk National University Medical School, Jeonju, Chonbuk 54907, Republic of Korea, Department of Oral Biochemistry and Institute of Biomaterials Implant, School of Dentistry, Wonkwang University, Iksan, Chonbuk 54538, Republic of Korea, Department of Surgery, Research Institute of Clinical Medicine of Chonbuk National University, Biomedical Research Institute of Chonbuk National University Hospital, Jeonju, Chonbuk 54907, Republic of Korea
Published online on: May 2, 2017 https://doi.org/10.3892/ol.2017.6108
Pages: 441-446

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Epigallocatechin gallate (EGCG), a major constituent of green tea, has potential as a treatment for a variety of diseases, including cancer. EGCG induces apoptosis and inhibits tumorigenesis through multiple signaling pathways in breast cancer cells. β‑catenin signaling modulators could be useful in the prevention and therapy of breast cancer. However, the precise anticancer effect of EGCG through the β‑catenin signaling pathway in breast cancer is unclear. The present study investigated the association between β‑catenin expression and clinicopathological factors of breast cancer patients, and the effect of EGCG on β‑catenin expression in breast cancer cells. β‑catenin expression was analyzed according to the clinicopathological factors of 74 patients with breast cancer. All patients were females diagnosed with invasive ductal carcinoma. Western blot analysis revealed that β‑catenin was expressed at higher levels in breast cancer tissue than in normal tissue. β‑catenin expression was associated with lymph node metastasis (P=0.04), tumor‑node‑metastasis stage (P=0.03) and estrogen receptor status (P<0.01). EGCG decreased MDA‑MB‑231 cell viability and significantly downregulated the expression of β‑catenin, phosphorylated Akt and cyclin D1. Remarkably, additive effects of LY294002 and wortmannin, two phosphatidylinositol‑3 kinase inhibitors, were observed. The present results suggest that EGCG inhibits the growth of MDA‑MB‑231 cells through the inactivation of the β‑catenin signaling pathway. Based on these promising results, EGCG may be a potential treatment for triple negative breast cancer patients.

View Figures

View References

1	Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al: Molecular portraits of human breast tumours. Nature. 406:747–752. 2000. View Article : Google Scholar : PubMed/NCBI
2	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar : PubMed/NCBI
3	Roodi N, Bailey LR, Kao WY, Verrier CS, Yee CJ, Dupont WD and Parl FF: Estrogen receptor gene analysis in estrogen receptor-positive and receptor-negative primary breast cancer. J Natl Cancer Inst. 87:446–451. 1995. View Article : Google Scholar : PubMed/NCBI
4	Gadducci A, Biglia N, Sismondi P and Genazzani AR: Breast cancer and sex steroids: Critical review of epidemiological, experimental and clinical investigations on etiopathogenesis, chemoprevention and endocrine treatment of breast cancer. Gynecol Endocrinol. 20:343–360. 2005. View Article : Google Scholar : PubMed/NCBI
5	Sartippour MR, Pietras R, Marquez-Garban DC, Chen HW, Heber D, Henning SM, Sartippour G, Zhang L, Lu M, Weinberg O, et al: The combination of green tea and tamoxifen is effective against breast cancer. Carcinogenesis. 27:2424–2433. 2006. View Article : Google Scholar : PubMed/NCBI
6	Sak K: Chemotherapy and dietary phytochemical agents. Chemother Res Pract. 2012:2825702012.PubMed/NCBI
7	Chisholm K, Bray BJ and Rosengren RJ: Tamoxifen and epigallocatechin gallate are synergistically cytotoxic to MDA-MB-231 human breast cancer cells. Anticancer Drugs. 15:889–897. 2004. View Article : Google Scholar : PubMed/NCBI
8	Graham HN: Green tea composition, consumption, and polyphenol chemistry. Prev Med. 21:334–350. 1992. View Article : Google Scholar : PubMed/NCBI
9	Nakachi K, Matsuyama S, Miyake S, Suganuma M and Imai K: Preventive effects of drinking green tea on cancer and cardiovascular disease: Epidemiological evidence for multiple targeting prevention. Biofactors. 13:49–54. 2000. View Article : Google Scholar : PubMed/NCBI
10	Kurahashi N, Sasazuki S, Iwasaki M, Inoue M and Tsugane S; JPHC Study Group, : Green tea consumption and prostate cancer risk in Japanese men: A prospective study. Am J Epidemiol. 167:71–77. 2008. View Article : Google Scholar : PubMed/NCBI
11	Yang CS, Landau JM, Huang MT and Newmark HL: Inhibition of carcinogenesis by dietary polyphenolic compounds. Annu Rev Nutr. 21:381–406. 2001. View Article : Google Scholar : PubMed/NCBI
12	Zhang M, Holman CD, Huang JP and Xie X: Green tea and the prevention of breast cancer: A case-control study in Southeast China. Carcinogenesis. 28:1074–1078. 2007. View Article : Google Scholar : PubMed/NCBI
13	Hsu YC and Liou YM: The anticancer effects of (−)-Epigalocathine-3-gallate on the signaling pathways associated with membrane receptors in MCF-7 cells. J Cell Physiol. 226:2721–2730. 2011. View Article : Google Scholar : PubMed/NCBI
14	Khan N, Afaq F, Saleem M, Ahmad N and Mukhtar H: Targeting multiple signaling pathways by green tea polyphenol (−)-epigallocatechin-3-gallate. Cancer Res. 66:2500–2505. 2006. View Article : Google Scholar : PubMed/NCBI
15	Stuart EC, Scandlyn MJ and Rosengren RJ: Role of epigallocatechin gallate (EGCG) in the treatment of breast and prostate cancer. Life Sci. 79:2329–2336. 2006. View Article : Google Scholar : PubMed/NCBI
16	Thangapazham RL, Singh AK, Sharma A, Warren J, Gaddipati JP and Maheshwari RK: Green tea polyphenols and its constituent epigallocatechin gallate inhibits proliferation of human breast cancer cells in vitro and in vivo. Cancer Lett. 245:232–241. 2007. View Article : Google Scholar : PubMed/NCBI
17	Goodin MG, Fertuck KC, Zacharewski TR and Rosengren RJ: Estrogen receptor-mediated actions of polyphenolic catechins in vivo and in vitro. Toxicol Sci. 69:354–361. 2002. View Article : Google Scholar : PubMed/NCBI
18	Roy AM, Baliga MS and Katiyar SK: Epigallocatechin-3-gallate induces apoptosis in estrogen receptor-negative human breast carcinoma cells via modulation in protein expression of p53 and Bax and caspase-3 activation. Mol Cancer Ther. 4:81–90. 2005.PubMed/NCBI
19	Boras-Granic K and Wysolmerski JJ: Wnt signaling in breast organogenesis. Organogenesis. 4:116–122. 2008. View Article : Google Scholar : PubMed/NCBI
20	Amado NG, Fonseca BF, Cerqueira DM, Neto VM and Abreu JG: Flavonoids: Potential Wnt/beta-catenin signaling modulators in cancer. Life Sci. 89:545–554. 2011. View Article : Google Scholar : PubMed/NCBI
21	Loh YN, Hedditch EL, Baker LA, Jary E, Ward RL and Ford CE: The Wnt signaling pathway is upregulated in an in vitro model of acquired tamoxifen resistant breast cancer. BMC Cancer. 13:1742013. View Article : Google Scholar : PubMed/NCBI
22	Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FI and Trotti A III: Part VII breastAJCC Cancer Staging Manual. 7th. Springer; New York, NY: pp. 347–376. 2010
23	Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar : PubMed/NCBI
24	Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, et al: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 353:1659–1672. 2005. View Article : Google Scholar : PubMed/NCBI
25	Foulkes WD, Smith IE and Reis-Filho JS: Triple-negative breast cancer. N Engl J Med. 363:1938–1948. 2010. View Article : Google Scholar : PubMed/NCBI
26	López-Knowles E, Zardawi SJ, McNeil CM, Millar EK, Crea P, Musgrove EA, Sutherland RL and O'Toole SA: Cytoplasmic localization of beta-catenin is a marker of poor outcome in breast cancer patients. Cancer Epidemiol Biomarkers Prev. 19:301–309. 2010. View Article : Google Scholar : PubMed/NCBI
27	Nelson CM and Chen CS: Cell-cell signaling by direct contact increases cell proliferation via a PI3K-dependent signal. FEBS Lett. 514:238–242. 2002. View Article : Google Scholar : PubMed/NCBI
28	Toker A and Newton AC: Cellular signaling: Pivoting around PDK-1. Cell. 103:185–188. 2000. View Article : Google Scholar : PubMed/NCBI
29	Peairs A, Dai R, Gan L, Shimp S, Rylander MN, Li L and Reilly CM: Epigallocatechin-3-gallate (EGCG) attenuates inflammation in MRL/lpr mouse mesangial cells. Cell Mol Immunol. 7:123–132. 2010.PubMed/NCBI